Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 11, 2000 - Issue 3
Submit an article Journal homepage
23
Views
3
CrossRef citations to date
0
Altmetric
Research Article

The use of antimalarials in dermatology

M Trehan Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
Pages 185-194 | Published online: 12 Jul 2009

  • Leden I, Antimalarial drugs - 350 years. Scand J Rheumatol (1981) 10: 307-12.
  • Wallace D, The history of antimalarials. Lupus (1996) 5: S2-3.
  • Brick JE, Quinine: the conquest of malaria and the beginning of the modern drug industrial complex. W V Med J (1999)95:64-5.
  • Wallace DJ, Antimalarial agents and lupus. Rheum Dis Clin North Am (1994)20:243-63.
  • Camisa C, Antimalarials. In: Wolverton S, Williams J (eds) Systemic drugs for skin diseases. W.B Saunders Company: Philadelphia. 1991, pp. 265-85
  • Furst DE, Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus (1996)5:811-15.
  • Tett SE, Cutler DJ, Day RO, Brown KF, Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol (1989) 27: 771-9.
  • Tett SE, Cutler DJ, Day RO, Brown KF, A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol (1988) 26: 303-13.
  • Tett SE, Cutler DJ, Day RO, Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J Pharm Sci (1992) 81: 155-9.
  • Behrens R, Travellers diarrhea: a controlled study of its effect on chloroquine and proguanil absorption. Trans R Soc Trop Med Hyg (1994) 88: 86-8.
  • Easterbrook M, Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol (1990) 25: 249-51.
  • Ettle E, Ogonor J, Essien K, Passage of chloroquine into semen. Br J Clin Pharmacol (1988) 26: 179-82.
  • Ziering CL, Rabinowitz LG, Esterly NB, Antimalarials for children: indications, toxicities, and guidelines {see comments}. J Am Acad Dermatol (1993) 28: 764-70.
  • Isaacson D, Elgart M, Turner ML, Anti-malarials in dermatology. Int J Dermatol (1982) 21: 379-95.
  • White N, Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet (1985) 10: 187-215.
  • Edstein M, Veenendaal J, Newman K, Hyslop R, Excretion of chloroquine, dapsone and pyrimethamine in human milk. Br J Clin Pharmacol. (1986) 22: 733-5.
  • Ogunbona K, Onyeji C, Bolaju O, Torimori S, Excretion of chloroquine and desethylchloroquine in human milk. Br J CLin Pharmacol (1987) 23: 473-6.
  • Cutler DJ, Maclntyre AC, Tett SE, Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl (1988) 24:142-57.
  • Koranda FC. Antimalarials. J Am Acad Dermatol (1981) 4: 650-5.
  • Fox R, Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus (1996) 5: S4-10.
  • Unanue K, Antigen presenting function of the macrophage. Annu Rev Immunol (1984) 2: 395-428.
  • Picot S, Peyron F, Vuillez JP et al, Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro. J Inject Dis (1991) 164: 8 30.
  • Hurst NP, French JK, Gorjatschko L, Betts WH, Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil Superoxide release. J Rhewnatol (1988) 15: 2 3-7.
  • Salmeron G, Lipsky PE, Immunosuppressive potential of antima]arials. Am J Med (1983) 75: 19-24.
  • Sjolin-Forsberg G, Berne B, Eggelte T, Karlsson-Parra A, In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol (1995) 75: 228-31.
  • Rosenberg FJ, Gimber-Phillips PE, Groblewski GE et al, Acetylsalicylic acid: inhibition of platelet aggregation in the rabbit. J Pharmacol Exp Ther (1971) 179: 410-8.
  • Petri M, Hellmann D, Hochberg M, Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus (1996) 5: 816-22.
  • Carter AK, Eban R, Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J (1974) 3: 94-5.
  • Madow B, Use of antimalarials as 'desludging' agents in vascular disease processes. JAMA (1960) 172: 1630-3.
  • Petri M, Hellmann D, Hochberg M et al, Arterial thrombotic events (TE) in SLE: The Baltimore Lupus Cohort Study. Arthritis Rheum (1994) 37: S297.
  • Wallace DJ, The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus (1996) 5: 859-64.
  • Quatraro A, Consoli G, Ceriello A, Giugliano D, Is there a role of chloroquine treatment in diabetes? A three case report. Diabete Metab (1988) 14: 666-7.
  • Quatraro A, Consoli G, Magno M et al, Hydroxychloroquine in decompensated, treatment-refractory noninsulindependent diabetes mellitus. A new job for an old drug? Ann Intern Med (1990) 112: 678-81.
  • Wallace DJ, Metzger AL, Stecher VJ et al, Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med (1990) 89: 322-6.
  • Blyth TH, McDonald AG, Cappell HA, Hunter JA, A comparison of hydroxychloroquine and myocrisin in rheumatoid arthritis (RA); does hydroxychloroquine have a favorable effect on the blood lipid profiler Br J Rheumatol (1994) 33(suppl): 149.
  • Hodis HN, Quismorio FPJ, Wickham E, Blankenhorn DH, The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus.J Rheumatol (1993) 20: 661-5.
  • Nayak V, Esdaile J, The efficacy of antimalarials in systemiclupus erythematosus. Lupus (1996) 5: 823-7.
  • Rynes RI, Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol (1997) 36: 799-805.
  • Rudnicki R, Gresham G, Rothfield N, The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol (1975) 2: 323-30.
  • The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N' Engl J Med (1991) 324:150-64.
  • CaIlen JP, Management of antimalarial-refractory cutaneous lupus erythematosus. Lupus (1997) 6: 203-8.
  • Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ, The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus (1993) 2: 813-15.
  • Wallace DJ, Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? {letter}. Arthritis Rheun( 1987) 30: 1435-6.
  • Balogh E, Nagy-Vezekenyi K, Forizs E, REM syndrome: an immediate therapeutic response to hydroxychloroquine sulphate. Acta Derm Venereol (1980) 60: 173-5.
  • Toonstra J, Wildschut A, Boer J et al, Jessner's lymphocytic infiltration of the skin: a clinical study of 100 patients. Arch Dermatol(1989) 125: 1525-30.
  • Liedtka J, Intralesional chloroquine for the treatment of cutaneous sarcoidosis. Int J Dermatol (1996) 35: 682-3.
  • Carlin MC, Ratz JL, A case of generalized granuloma annulare responding to hydroxychloroquine. Cleve Clin J Med (1987) 54:229-32.
  • Petersen CS, Thomsen K, High-dose hydroxychloroquine treatment of porphyria cutanea tarda. J Am Acad Dermatol (1992)26:614-19.
  • Vails V, Ena J, Enriquez-de Dalmanca R, Low dose oral chloroquine with porphyria cutanea tarda. J Dermatol Sci (1994)7: 169-75.
  • Kruize AA, Hene RJ, Kallenberg CG et al, Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheuni Dis (1993) 52: 360-64.
  • Fox RI, Dixon R, Guarrasi V, Krubel S, Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus(1996) 5: 831-6.
  • Duncan MR, Capell HA, The use of antimalarials in combination with other disease modifying agents in RA - the British experience. Lupus (1996) 5: 850-8.
  • Sokol RJ, Lichtenstein PK, Earrell MK, Quinacrine hydrochloride induced yellow discoloration of the skin in children. Pediatrics(1982) 69: 2 32-3.
  • Leigh I, Kennedy C, Ramsey f, Henderson W, Mepacrine pigmentation in systemic lupus erythematosus. New data from an ultrastructural, biochemical and analytical electron microscopic investigation. Br J Dermatol (1979) 101: 147-53.
  • Selvaag K. Chloroquine induced vitiligo. A case report and review of the literature. Acta Demi Venereol (1996) 76: 166-7.
  • Bauer K. Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). J Am Acad Dermatol (1981) 4: 239-44.
  • Assier-Bonnet H. Saada V. Bernier M et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine. Dermatology (1996) 193: 70-1.
  • Kuflik E. Effect of antimalarial drugs on psoriasis. Cutis (1980) 26:153-5.
  • Abel K. DiCieco L. Orenberg K. Drugs in exacerbation of psorlasis.: Am Acad Dermatol (1986) 15: 1007-22.
  • Slagel GA. James WD. Plaquenil-induced erythroderma. J Am Acad Dermatol (1985) 12: 857-62.
  • Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med (1988) 85:2 3-9.
  • Hobbs H. Sorsby A. Friedman A. Retinopathy following chloroquine therapy. Lancet (1959) 2: 478-80.
  • Ramsey M. Fine B. Chloroquine toxicity in the human eye. Am J Ophtalmol (1972) 73:229-35.
  • Spalton DJ. Retinopathy and antimalarial drugs - the British experience, Lupus (1996) 5: 870-2.
  • Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med (1983) 75:40-5.
  • Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol (1991) 23: 292-6.
  • Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J (1992) 85:274-9.
  • Mavrikakis M. Papazoglou S. Sfikakis PP et al. Retinal toxicity in long term hydroxychloroquine treatment. AnnRheum Dis (1996) 55: 187-9.
  • Olson NY. Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumotol (1989) 16:1545-7.
  • Fox JN. Klapman MH. Rowe L. Lupus profundus in children: treatment with hydroxychloroquine. J Am Acad Dermatol (1987) 16:839-44.
  • Rasmussen J. Antimalarials: are they safe to use in children? Pediatr Dermatol (1983) 1: 89-91.
  • Wallace D. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rhem (1989)18: 282-96.
  • Lvevy M. Buskila D. Gladman DD et al. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perimatol (1991)8:174-8.
  • Khamashta MA. Buchanan NM. Hughes GR. The use of hydroxychloroquine in lupus pregnancy: the British experience.Lupus (1996) 5: 865-6.
  • Buchanan NM. Toubi E. Khamashta MA et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis (1996) 55: 486-8.
  • Parke AL Rothfield NF. Antimalarial drugs in pregnancy the North American experience, Lupus (1996) 5: 867-9.
  • Beattie C. Beaudet E. Davis P et al. Antimalarial Workshop Report. J Rhenmatol (1997) 24:139 3-5.
  • Easterbrook M. Current concepts in monitoring patients on antimalarials.Aust NZ J Opthalmol (1998) 26:101-3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.